Business Wire

Spirent Positions To Assure Next-Generation Device And Network Performance

Del

Spirent Communications plc (LSE:SPT), the trusted provider of test, measurement, assurance and analytics solutions for next-generation devices and networks, today announced the company-wide “Promise. Assured.” business initiative to leverage its proven innovation to pursue emerging technologies and new industries and extend into service provider and enterprise networks. The company will focus on assuring customer performance and revenues with solutions for 5G, lifecycle service assurance and analytics, and cybersecurity. It will also explore new business opportunities in virtualization, autonomous vehicles and automotive.

“Markets are transforming rapidly and our role in this new frontier is to march alongside our customers, not just as solution providers but true partners,” said Eric Hutchinson, CEO, Spirent. “That means delivering insights that influence and support strategies for revenue growth and cost savings throughout the organizations we serve, as we help accelerate the transition of devices, equipment and applications from the lab into the operational network.”

Spirent’s focus on 5G, lifecycle service assurance and analytics for better customer experiences and cybersecurity to simplify and validate defenses will include solutions for development, benchmarking and management of mobile networks, Ethernet business services, and virtualized network functions. It will see the company working with customers in new ways, leveraging deep expertise and experience in:

  • 5G – As 5G investments gain momentum globally, Spirent enables and assures 5G products and services, including hybrid networks. The company will continue to create 5G test solutions for development of 5G devices and network equipment, and expand focus to include service assurance and analytics of 5G networks.
  • Lifecycle Service Assurance – As great customer experiences become the next competitive battleground, Spirent will deliver real-time operational analytics to address issues before they impact service performance and customer experience, leveraging automation, analytics and active testing technologies. This includes expanding the company’s VisionWorks solutions to 5G and IoT and incorporating artificial intelligence, machine learning and big data analytics into new applications.
  • Cybersecurity – Spirent tests products and networks for security vulnerabilities, offering cybersecurity products that simulate a wide range of scenarios with real world traffic mixes and services that provide industry-leading expertise. The company fosters collaborative industry efforts, including through its work as a founding member of NetSecOPEN, the open industry group that brings together security product vendors, test tool vendors and test labs to develop test specifications. Spirent will expand its security products and services, including new data breach detection assessment capabilities as it accelerates growth in this market.

Spirent is recognized globally as a leader in lab-based high-speed Ethernet, positioning and mobile network infrastructure testing, and service assurance systems for service providers. The company will continue to advance in these markets while innovating toward cybersecurity solutions, and automated testing and development of autonomous service assurance solutions. It will also focus on validating automotive Ethernet performance and evaluating vehicle-to-vehicle, vehicle-to-infrastructure and autonomous vehicle implementation readiness.

The “Promise. Assured.” initiative is supported by a new branding campaign that emphasizes Spirent’s capabilities to bring clarity to increasing device and network complexity, and serve as trusted advisors to help enable and assure the promises Spirent’s customers make to their customers.

About Spirent

Spirent Communications plc. (LSE: SPT) offers test, measurement, analytics and assurance solutions for next-generation devices and networks. The company provides products, services and information for high-speed Ethernet, positioning and mobile network infrastructure markets, with expanding focus on service assurance, cybersecurity and 5G. Spirent is accelerating the transition of connected devices, network equipment and applications from development labs to the operational network, as it continues to innovate toward fully-automated testing and autonomous service assurance solutions.

For more information, please visit www.spirent.com and follow us on LinkedIn, Twitter and Facebook.

Contact information

Spirent Communications plc.
Mark Price, +44 7725 724834
mark.price@spirent.com
www.spirent.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an